ALPMY News and Press, Astellas Pharma Inc. ADR From 01/26/24

2024-01-26 07:39:18 ET More on Apellis Pharmaceuticals Apellis Pharmaceuticals: Focus Shifts Toward Market Share After Apparent Safety Resolution Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - E...

2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...

2024-01-09 05:49:53 ET Japanese drugmaker Astellas Pharma ( OTCPK:ALPMY ) said on Monday that the U.S. Food and Drug Administration (FDA) has declined to approve the biologics license application of its experimental gastric cancer drug due to issues related to a third-party manufact...

Astellas Provides Update on Zolbetuximab Biologics License Application in U.S. PR Newswire TOKYO , Jan. 8, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced the U.S. Food and Drug Administrati...

2023-12-31 01:55:00 ET Summary Elpiscience Biopharma forms a $1.7 billion collaboration with Astellas Pharma to develop a bispecific macrophage engager. AstraZeneca acquires Gracell Biotech in a deal worth up to $1.2 billion, including a clinical stage CAR-T therapy. Jinan Qil...

2023-12-28 04:45:39 ET More on Astellas Pharma FDA approves Keytruda/Padcev combo therapy for bladder cancer Biden eyes seizing patents of taxpayer-funded drugs in bid to slash prices Seeking Alpha’s Quant Rating on Astellas Pharma ADR For further deta...

Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager PR Newswire SHANGHAI and SUZHOU, China and TOKYO , Dec. 28, 2023 /PRNewswire/ -- Elpiscience Biopharma, Ltd. (Chairman and C...

2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...

Astellas Completes Acquisition of Propella Therapeutics PR Newswire TOKYO , Dec. 21, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") announced today that it has completed the acquisition of Propella Therape...

EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children PR Newswire - Astellas contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium - TOKYO , ...